About the ACCESS DMD™ program
The intent of an expanded access program is to provide patients with access to investigational medication for serious diseases or conditions where there is no comparable or satisfactory alternative therapy available. The ACCESS DMD™ program will enable participating physicians to obtain and provide deflazacort*, an investigational medication for eligible U.S. patients diagnosed with DMD, while it is under development. The FDA has authorized the use of deflazacort* for eligible patients with DMD under the ACCESS DMD™ expanded access program.
Physicians are invited to register themselves and their qualifying patients for ACCESS DMD™. Participating physicians will be able to arrange (via a specialty pharmacy) for deflazacort* to be delivered directly to their patients or patients’ caregivers in accordance with the expanded access protocol and regulatory requirements applicable to expanded access uses. ACCESS DMD™ participants will receive deflazacort* at no cost while participating in the program.
*Deflazacort is an investigational medication that has not been approved by the Food and Drug Administration (FDA) and is therefore not proven to be safe and effective.